[Lu-177]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu
The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2018
This study was sponsored by the Peter MacCallum Cancer Centre (Melbourne, VIC, Australia). <SUP>177</SUP>Lu (no carrier added) was supplied by the Australian Nuclear Science and Technology Organisation (ANSTO, Sydney, Australia) and PSMA-617 by Advanced Biochemical Compounds (ABX, Radeberg, Germany). MSH is supported by a Clinical Fellowship Award from the Peter MacCallum Foundation and a Movember Clinical Trials Award awarded through the Prostate Cancer Foundation of Australia's Research Program. SS is supported by a Clinical Fellowship Award from the Peter MacCallum Foundation and by the John Mills Young Investigator Award from Prostate Cancer Foundation of Australia. RJH is supported by a National Health and Medical Research Foundation of Australia Practitioner Fellowship. We thank the nuclear medicine and nursing staff at the Peter MacCallum Cancer Centre and all the patients who agreed to participate in the study. We also thank Mathias Bressel (biostatistican) for analysis of the quality-of-life data.